Filing Flows › Parabilis Medicines (PBLS) › Stock forecast & fair value
Parabilis Medicines (PBLS) stock forecast and price target
Parabilis Medicines (PBLS) trades at $28.53. 5 analysts' median price target is $40.00 (+40%), from $40.00 to $45.00.
Parabilis Medicines' latest quarter
Parabilis Medicines, Q2 2026: revenue $148K, net loss $52.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PBLS stock?
The median of 5 analysts' 12-month targets is $40.00, +40% from $28.53; the range is $40.00 to $45.00. The average rating is strong buy.
Does Parabilis Medicines usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is PBLS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.